FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average b	ourden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(c). S	ee Instruction 1	0.																	
Name and Address of Reporting Person* Kamocsay Jennifer				2. Issuer Name and Ticker or Trading Symbol Akoya Biosciences, Inc. [AKYA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
(Last) (First) (Middle) C/O AKOYA BIOSCIENCES, INC. 100 CAMPUS DRIVE, 6TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 11/19/2024								Officer (give title Other (specify below) Chief Legal Officer							
(Street) MARLBOROUGH MA 01752 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)							Lin	Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or I	Bene	eficia	ally Ow	ned			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Execution Date,				s Acquired (A) of (D) (Instr. 3, 4			nd Secu Bene	nount of rities ficially ed Following	Forn	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A)) or)	Price	Trans	action(s) 3 and 4)			(
Common Stock 11/19/2					2024				A 87,500 ⁽¹⁾)	A	\$ <mark>0</mark> (2	2) 1	186,717		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any			ransaction of ode (Instr. Derivative		Expirat	Exercisable and ion Date /Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		J nstr.	8. Price o Derivative Security (Instr. 5)		ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	of	nber ires					

Explanation of Responses:

- 1. The restricted stock units shall vest as to 50% on the first anniversary of the first day of the month subsequent to the date of grant (the "First Vesting Date") with the remainder vesting as follows: 25% on the date that is three months following the First Vesting Date; 25% on the date that is nine months following the First Vesting Date; and 25% on the date that is twelve months following the First Vesting Date.
- 2. Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.

/s/ Jennifer Kamocsay, by

Brian McKelligon, as 11/21/2024

Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.